IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to protect Kids' kidneys from rare disease
Disease control Recruiting nowThis study is testing whether the drug ravulizumab can help children and teenagers (ages 2-18) with IgA nephropathy, a kidney disease where the immune system attacks the kidneys. Participants will receive the drug through an IV to see if it reduces protein in their urine and slow…
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 02, 2026 06:41 UTC
-
New shot tested to halt damage in serious kidney diseases
Disease control Recruiting nowThis study is testing an investigational drug called atacicept for several autoimmune kidney diseases, including IgA Nephropathy and Focal Segmental Glomerulosclerosis. It aims to see if weekly injections are safe and can reduce protein in the urine and help preserve kidney funct…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug trial targets rare kidney diseases
Disease control Recruiting nowThis study is testing an experimental drug called ADX-038 for people with specific immune-related kidney diseases. Researchers will enroll 45 adults with conditions like IgA nephropathy or C3 glomerulopathy to see if the drug is safe and helps control their kidney disease. The go…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Major trial tests new drug to protect kidneys from silent disease
Disease control Recruiting nowThis study is testing whether the drug ravulizumab can slow the progression of IgA nephropathy (IgAN), a kidney disease that can lead to kidney failure. About 510 adults with IgAN who are at high risk of their disease getting worse will receive either the study drug or a placebo …
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC